REFERENCES
1. Ataey A, Jafarvand E, Adham D, Moradi-Asl E. The relationship between obesity, overweight, and the human development index in world health organization eastern mediterranean region countries. J Prev Med Public Health. 2020;53:98-105.
2. Tabaja C, Younis A, Santageli P, et al. Impact of obesity on catheter ablation of atrial fibrillation: patient characteristics, procedural complications, outcomes, and quality of life. J Cardiovasc Electrophysiol. 2023;34:1648-57.
3. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017;70:2022-35.
4. Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the atherosclerosis risk in communities (ARIC) study. Circulation. 2011;123:1501-8.
5. Turagam MK, Musikantow D, Whang W, et al. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials. JAMA Cardiol. 2021;6:697-705.
6. Prasitlumkum N, Chokesuwattanaskul R, Kaewput W, et al. Utilization and in-hospital complications of catheter ablation for atrial fibrillation in patients with obesity and morbid obesity. Clin Cardiol. 2022;45:407-16.
7. Letsas KP, Siklódy CH, Korantzopoulos P, et al. The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. Int J Cardiol. 2013;164:94-8.
8. Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123:646-51.
9. Urbanek L, Bordignon S, Chen S, et al. Impact of body mass index on cryoablation of atrial fibrillation: Patient characteristics, procedural data, and long-term outcomes. J Cardiovasc Electrophysiol. 2022;33:1106-15.
10. Donnellan E, Wazni OM, Kanj M, et al. Impact of risk-factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2020;31:1979-86.
11. Joglar JA, Chung MK, Armbruster AL, et al. ; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-e156.
12. Meulendijks ER, Krul SPJ, Baalman SW, et al. Circulating adipose tissue proteins involved in atrial fibrillation: an explorative scoping review. Trends Cardiovasc Med. 2024;34:148-58.
13. McCauley MD, Hong L, Sridhar A, et al. Ion channel and structural remodeling in obesity-mediated atrial fibrillation. Circ Arrhythm Electrophysiol. 2020;13:e008296.
14. Mahajan R, Lau DH, Brooks AG, et al. Atrial fibrillation and obesity: reverse remodeling of atrial substrate with weight reduction. JACC Clin Electrophysiol. 2021;7:630-41.
15. Sha R, Baines O, Hayes A, et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options. J Am Heart Assoc. 2024;13:e032277.
16. Mangiafico V, Saberwal B, Lavalle C, et al. Impact of obesity on atrial fibrillation ablation. Arch Cardiovasc Dis. 2020;113:551-63.
17. Calvert P, Mills MT, Gupta D. Duration of atrial fibrillation: how much is too much? Heart Rhythm 2024;21:741-2.
18. Peigh G, Wasserlauf J, Vogel K, et al. Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32:2097-104.
